Guidelines for Clotting Studies in Cancer Patients

A Falanga; T Barbui; F R Rickles; M N Levine

doi:10.1055/s-0038-1649619

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 70(03): 540-542
DOI: 10.1055/s-0038-1649619

Scientific and Standardization Committee Communication

Schattauer GmbH Stuttgart

Guidelines for Clotting Studies in Cancer Patients

For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis

A Falanga

¹The Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy

,

T Barbui

¹The Divisione di Ematologia, Ospedali Riuniti, Bergamo, Italy

,

F R Rickles

²The Div. Hematology/Oncology, Univ. of Connecticut, Farmington, CT and the Veterans Administration Med. Center, Newington, CT, USA

,

M N Levine

³The Ontario Cancer Treatment and Research Foundation, Hamilton Regional Cancer Centre, Hamilton, Ontario, Canada

› Author Affiliations

Abstract

PDF Download

PDF (673 kb)

References

References
1 Sun NC, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study in one hundred eight patients. Part I. Coagulation study. Am J Clin Pathol 1979; 71: 10-16
2 Sack GH, Levin J, Bell W. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasma: clinical, pathologic, and therapeutic features. Medicine 1977; 56: 1-37
3 Edwards RL, Rickles FR, Moritz TE, Henderson WG, Zacharski LR, Forman WB, Cornell CJ, Forcier RJ, O'Donnell JF, Headley E, Kim SH, O'Dell R, Tornyos K, Kwaan HC. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987; 88: 596-602
4 Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E, Kim SH, O'Donell JF, O'Dell R, Tornyos K, Kwaan HC. Effect of Warfarin on survival in carcinoma of the lung, colon, head and neck, and prostate. Cancer 1984; 53: 2046-2052
5 Zacharski LR, Moritz TE, Baczek LA, Rickles FR, Edwards RL, Forman WB, Forcier RJ, Cornell CJ, Haakenson CM, Ballard HS, Crum ED, Johnson GJ, Levine J, Hong WK, O'Donnell JF, Schilsky RL, Ringenberg QS, Robert F, Spaulding MB, Tornyos K, Williams C, Zucker S, Faulkner IICS, Eaton WL, Hoppel CL. Effect of Mopidamol on survival in carcinoma of the lung and colon: Final report of Veterans Administration Cooperative study No. 188. J Natl Cancer Inst 1988; 80: 90-97
6 Rickles FR, Levine MN, Edwards RL. Hemostatic alterations in cancer patients. Cancer Met Rev 1992; 1: 241-260
7 Poggi A, Polentarutti N, Donati MB, de Gaetano G, Garattini S. Blood coagulation changes in mice bearing Lewis Lung carcinoma, a metastasizing tumor. Cancer Res 1977; 37: 272-277
8 Lyman GH, Bettigole RE, Robson E, Ambrus JL, Urban H. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978; 41: 1113-1122
9 Budzynski AZ, Marder VJ, Parker ME, Shames P, Brizuela BS, Olexa S. Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin. Blood 1979; 54: 794-804
10 Nossel HL. Radioimmunoassays of fibrinopeptides in relation to intravascular coagulation and thrombosis. New Engl J Med 1976; Aug 19: 428-432
11 Kudryk B, Robinson D, Netré C, Hessel B, Blomback M, Blomback B. Measurement in human blood of fibrinogen/fibrin fragments containing the Bβ_15-42 sequence. Thromb Res 1982; 25: 277-291
12 Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70: 343-350
13 Lau HK, Rosenberg RD. The isolation and characterization of a specific antibody directed against the thrombin-antithrombin complex. J Biol Chem 1980; 255: 5885-5893
14 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with a enzyme-linked immunosorbent assay. Throm Haemost 1988; 59: 101-106
15 Harker LA, Slichter SJ. Platelet and fibrinogen consumption in man. New Engl J Med 1972; 287: 999-1005
16 Kaplan KL. Proteins secreted by platelets: significance in detecting thrombosis. Adv Exper Med Biol 1978; 102: 105-120
17 Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-473
18 Wehmeir A, Tschope D, Esser J, Menzel C, Nieuwenhuis HK, Schneider W. Circulating activated platelets in myeloproliferative disorders. Thromb Res 1991; 61: 271-278
19 Gaddiucci A, Baicchi U, del Bravo B, Marrai R, Vispi M, Fosella PV, Fioretti P. The assessment of the hemostasis system in patients with ovarian and cervical carcinoma. The Cancer J 1991; 4: 183-187
20 Levine MN, Brownman GP, Gent M, Goodyear M. When is a prognostic factor useful?: A guide for the perplexed. J Clin One 1992; 9: 348-356
21 Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Marziali S, Barbui T. Hemostatic system activation in patients with Lupus anticoagulant and Essential Thrombocytemia. Sem Hemost Thromb. in press 1993
22 Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero E, Marassi A, D'Angelo A, Barbui T. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Submitted 1993